Every 10-Q that Vystar Corp (VYST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VYST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VYST filings page.
Vystar Corporation reported very small Q2 2026 revenue of $7,767, down from $11,615 a year earlier, and a Q2 net loss attributable to Vystar of $225,293. For the first six months of 2026, revenue was $13,914 with a net loss of $590,072.
Cash from continuing operations was $109,845 at June 30, 2026, but current liabilities totaled $7.7 million, producing a working capital deficit of about $7.2 million and an accumulated deficit near $62 million. Total stockholders’ deficit was $7.1 million, and derivative liabilities were $469,153. Management states there is substantial doubt about the company’s ability to continue as a going concern and highlights dependence on new financing and revenue growth.
Operations rely heavily on air purification units (85% of year-to-date sales), and one customer represented 53% of Q2 revenue. Subsequent to quarter-end, Vystar entered a joint venture to co-own r3alm, Inc., issuing 8,371 Series B preferred shares, and holds a court-awarded attorneys’ fee recovery of about $497,440 from resolved EMA litigation.
Vystar Corporation reported another quarterly loss and continued financial strain for the three months ended March 31, 2026. Revenue fell to $6,147 from $12,657 a year earlier, while gross profit was essentially flat at $4,272. Operating expenses of $281,122 produced a loss from operations of $276,850 and a net loss of $364,779, or $0.01 per share.
Liquidity remains extremely tight. Cash was only $9,907 against total current liabilities of $7,338,549, resulting in a working capital deficit of about $7 million and a stockholders’ deficit of $6,900,522. Management notes an accumulated deficit of roughly $61.7 million and explicitly states there is substantial doubt about the company’s ability to continue as a going concern.
The balance sheet is burdened by related party debt, including a Blue Oar term convertible note with a 12% rate and associated derivative liabilities of $423,632, plus defaulted notes and arrears to the Rotman family. Capital remains highly structured, with three series of cumulative convertible preferred stock that could convert into 30,712,937 common shares, far exceeding the 24,621,094 common shares currently outstanding.
There are a few offsetting developments. Vystar successfully prevailed in long-running EMA Financial litigation and was awarded $497,439.58 in attorneys’ fees, and it holds federal net operating loss carryforwards of about $39.2 million. Subsequent to quarter-end, the company signed a binding letter of intent to acquire 50% of Capital R3alm, Inc. in exchange for Series B preferred shares that would give Capital R3alm a 34% ownership stake in Vystar, aiming to expand into a Web3-focused financial technology ecosystem alongside its existing RxAir air purification and Vytex latex businesses.
Vystar Corporation reported Q3 2025 results showing very limited sales and ongoing losses. Revenue was $20,385, led by air purification units of $14,812 (72.7% of sales). Gross profit was $15,365, offset by operating expenses of $262,341, resulting in an operating loss of $246,976 and a net loss of $271,387 (basic and diluted loss per share $0.01). For the nine months, revenue was $44,657 with a net loss of $1,236,593.
Liquidity remains strained: cash was $16,584, current liabilities totaled $6,725,826 against current assets of $390,602, and stockholders’ deficit was $(6,242,094). Management states there is substantial doubt about the company’s ability to continue as a going concern.
The balance sheet includes a related party term note (Blue Oar) with a carrying amount of approximately $750,000 and a related derivative liability of $356,142. Share-based compensation expense was $199,097 in Q3. Common shares outstanding were 22,485,017 as of November 12, 2025.